CARBILEV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARBILEV (CARBILEV).
Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability in the central nervous system. Levodopa is converted to dopamine in the brain by aromatic L-amino acid decarboxylase (AAAD), replenishing striatal dopamine.
| Metabolism | Carbidopa is metabolized in the liver via O-methylation and N-glucuronidation. Levodopa is metabolized by aromatic L-amino acid decarboxylase and catechol-O-methyltransferase (COMT). |
| Excretion | Renal: ~80% as metabolites (mostly 3-O-methyldopa), 10% as dopamine; fecal: ~10% via biliary elimination. |
| Half-life | Carbidopa: 1-2 hours; Levodopa: 0.75-1.5 hours (prolonged to 1.5-2 hours with carbidopa). Carbidopa does not cross BBB; levodopa half-life reflects peripheral decarboxylase inhibition. |
| Protein binding | Levodopa: ~10% bound (albumin); Carbidopa: ~36% bound (albumin). |
| Volume of Distribution | Levodopa: 0.5-1.5 L/kg (large Vd indicates extensive tissue distribution, including CNS via LAT1 transporter); Carbidopa: 0.5-1 L/kg (limited CNS penetration). |
| Bioavailability | Oral: Levodopa ~30% alone, increased to ~50-75% with carbidopa (due to inhibition of peripheral decarboxylation); controlled-release: ~70% of immediate-release. |
| Onset of Action | Oral immediate-release: 30 minutes to 1 hour; controlled-release: 1-2 hours. |
| Duration of Action | Immediate-release: 4-6 hours; controlled-release: 4-8 hours with less fluctuation; clinical benefit may wane with disease progression. |
Carbidopa/Levodopa: 1 tablet of 25 mg/100 mg or 10 mg/100 mg orally 3 times daily, titrated up to 8 tablets per day based on response.
| Dosage form | TABLET, FOR SUSPENSION |
| Renal impairment | No specific dosage adjustment recommended for mild-to-moderate renal impairment. Use caution in severe impairment (GFR <30 mL/min) and consider dose reduction due to potential accumulation. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh Class C). For Child-Pugh Class A or B, no specific adjustment recommended but monitor for adverse effects. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. |
| Geriatric use | Lower initial doses recommended (e.g., 10 mg/100 mg 3 times daily). Titrate slowly to avoid orthostatic hypotension, confusion, and hallucinations. Monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARBILEV (CARBILEV).
| Breastfeeding | Levodopa is excreted in breast milk; M/P ratio unknown. Carbidopa levels in milk are minimal. Potential for infant adverse effects (e.g., drowsiness). Use caution; benefits likely outweigh risks in Parkinson's disease. |
| Teratogenic Risk | Carbidopa/Levodopa: First trimester: Limited human data, animal studies show fetal harm at high doses; risk cannot be excluded. Second/Third trimesters: No specific malformation pattern reported; monitor for intrauterine growth restriction. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Concurrent use with nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine)","Narrow-angle glaucoma","Known hypersensitivity to any component","Suspicious, undiagnosed skin lesions or history of melanoma"]
| Precautions | ["May cause neuroleptic malignant syndrome (NMS) on abrupt withdrawal","May cause dyskinesias or psychiatric disturbances","Risk of melanoma: periodic skin examinations recommended","May increase intraocular pressure in glaucoma patients","Caution in patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic, or endocrine disease","May cause urine, sweat, or saliva discoloration (red, brown, or black)"] |
| Food/Dietary | Avoid high-protein meals (e.g., meat, fish, dairy, eggs) within 1-2 hours before and after dosing, as protein can reduce levodopa absorption. Iron supplements and iron-rich foods may also decrease absorption. Pyridoxine (vitamin B6) in large doses can counteract the effects. |
Loading safety data…
| Maternal: Monitor BP, motor symptoms, signs of hepatic/renal toxicity. Fetal: Ultrasound for growth restriction and anomalies; neonatal assessment for transient extrapyramidal effects. |
| Fertility Effects | Data limited. No known effect on fertility in animal studies. Clinical evidence insufficient; theoretical risk of hormonal alterations. |
| Clinical Pearls | Carbidopa-levodopa (Carbilev) should be taken on an empty stomach for optimal absorption, but if gastrointestinal upset occurs, it can be taken with a low-protein snack. Avoid high-protein meals as they compete for absorption. Do not crush or chew extended-release formulations. Monitor for dyskinesias and 'on-off' phenomena; adjust dosing schedule accordingly. Abrupt withdrawal may precipitate neuroleptic malignant syndrome. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly. · May cause dizziness or drowsiness; avoid driving until you know how it affects you. · Report any uncontrolled movements or mood changes. · Avoid high-protein meals around dose times. · If you miss a dose, take it as soon as you remember unless it's close to the next dose; do not double up. · Urine, sweat, or saliva may turn dark (reddish-brown); this is harmless. |